Goldman Sachs Group Inc. began coverage on shares of ChemoCentryx (NASDAQ:CCXI) in a report released on Monday, TheFlyOnTheWall.com reports. The firm issued a neutral rating and a $7.00 price objective on the stock. ChemoCentryx Inc (NASDAQ:CCXI) stock opened at $7.60 in last trading session, and closed at $7.02, trading in the range of $6.88 – $7.65. The stock showed a positive weekly performance of 8.33%.
Pacific Biosciences of California (NASDAQ:PACB) average recommendation is hold with average target price $5.63. Pacific Biosciences of California (NASDAQ:PACB) shares closed at $6.99 on last trade day, by losing -4.90%. Stock 52 week range is $1.95 – $8.20. Company’s market capitalization is $462.40 billion. Relypsa Inc (NASDAQ:RLYP) stock rose 4.16% and finished the last session at $38.03. The EPS of the stock remained -3.96. Company’s market capitalization is $1.09 billion.
BMO Capital Markets upgraded shares of TESARO Inc (NASDAQ:TSRO) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning, TheFlyOnTheWall.com reports. The firm currently has $46.00 price target on the stock, up from their previous price target of $36.00. TESARO Inc (NASDAQ:TSRO) stock opened at $36.25 in last trading session and closed at $35.14. The 52 week range of the stock is $17.77 – $51.95 and the day range was $33.65 – $36.25.
Repligen Corporation (NASDAQ:RGEN) announced that it has entered into an asset purchase agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) to advance Repligen’s histone deacetylase inhibitor (HDACi) portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Repligen Corporation (NASDAQ:RGEN) shares closed at $14.50 on last trade day, by losing -1.99%. Stock 52 week range is $5.73 – $14.59. Company’s market capitalization is $455.65 million.